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A B S T R A C T
Macrophage colony-stimulating factor (CSF1) is an essential growth factor to control the proliferation, differ-
entiation and survival of cells of the macrophage lineage in vertebrates. We have previously produced a re-
combinant chicken CSF1-Fc fusion protein and administrated it to birds which produced a substantial expansion
of tissue macrophage populations. To further study the biology of CSF1 in the chicken, here we generated anti-
chicken CSF1 antibodies (ROS-AV181 and 183) using CSF1-Fc as an immunogen. The specific binding of each
monoclonal antibody was confirmed by ELISA, Western blotting and immunohistochemistry on tissue sections.
Using the anti-CSF1 antibodies, we show that chicken bone marrow derived macrophages (BMDM) express CSF1
on their surface, and that the level appears to be regulated further by exogenous CSF1. By capture ELISA cir-
culating CSF1 levels increased transiently in both layer and broiler embryos around the day of hatch. The levels
of CSF1 in broilers was higher than in layers during the first week after hatch. Antibody ROS-AV183 was able to
block CSF1 biological activity in vitro and treatment of hatchlings using this neutralising antibody in vivo im-
pacted on some tissue macrophage populations, but not blood monocytes. After anti-CSF1 treatment, CSF1R-
transgene reporter expressing cells were reduced in the bursa of Fabricius and cecal tonsil and TIM4+ Kupffer
cells in the liver were almost completely ablated. Anti-CSF1 treatment also produced a reduction in overall bone
density, trabecular volume and TRAP+ osteoclasts. Our novel neutralising antibody provides a new tool to study
the roles of CSF1 in birds.
1. Introduction
Macrophage colony-stimulating factor (CSF1) controls the pro-
liferation, differentiation and survival of cells of the macrophage
lineage in mammals and birds (Chitu and Stanley, 2017; Garceau et al.,
2015; Hume et al., 2019; Jenkins and Hume, 2014; Jenkins et al.,
2013). CSF1 acts by binding to a tyrosine kinase receptor (CSF1R),
which is encoded by the c-fms proto-oncogene (Sherr et al., 1985).
Expression of CSF1R is largely restricted to mononuclear phagocytes
(Rojo et al., 2017), but in mammals is detected on trophoblast cells
(Arceci et al., 1989; Regenstreif and Rossant, 1989) and in chickens it is
detected at low levels on heterophil granulocytes (Balic et al., 2014)
and antigen sampling follicular epithelial cells in mucosal lymphoid
associated tissues (Balic et al., 2019; Sutton et al., 2018). A second li-
gand for CSF1R, interleukin 34 (IL-34) has been identified (Lin et al.,
2008); however, its expression is more tissue restricted than CSF1
(Wang et al., 2012) and the functions and signalling activities of these
CSF1R ligands are not identical (Chihara et al., 2010; Liu et al., 2012;
Wei et al., 2010). Both chicken CSF-1 and IL-34 were shown to elicit
macrophage growth from chicken BM cells in culture (Garceau et al.,
2010). We previously produced a recombinant chicken CSF1-Fc fusion
protein (Garceau et al., 2015). As in mice (Gow et al., 2014), CSF1-Fc
administration to birds produced a substantial expansion of tissue
macrophage populations (Garceau et al., 2015). Mutation of Csf1 in
mice (op/op) produces a substantial reduction of tissue macrophage
populations alongside pleiotropic impacts on somatic growth and de-
velopment and variable impacts in cancer and inflammatory disease
models (Chitu and Stanley, 2006).
Some of these impacts are mimicked by neonatal treatment with
neutralising anti-CSF1 antibody, when CSF1 levels are highest (Wei
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et al., 2005) or following prolonged treatment of adults with anti-
CSF1R antibody (MacDonald et al., 2010; Sauter et al., 2014). More
recently, neutralising monoclonal antibodies against mouse CSF1 and
IL34 were developed and shown to have selective impacts on tissue
macrophage populations in vivo (Lin et al., 2019). To support studies of
the function of CSF1/CSF1R signalling in birds, we previously gener-
ated CSF1R reporter transgenic lines (Balic et al., 2014) and an anti-
CSF1R antibody (Garcia-Morales et al., 2014). The antibody provides a
marker for blood monocytes and tissue macrophages (CD115), but it
did not block binding of CSF1 and signalling by the receptor.
In the current study we describe the production and characterisation
of a novel anti-chicken CSF1 monoclonal antibody and show its appli-
cations in Western blot, capture ELISA and neutralising assays. We
show here that in chicken CSF1 is produced at high levels by mature
macrophages themselves and contributes to the development of the
immune system in the post hatch period. We discuss the extent to which
some of these insights may also be applicable to mammalian macro-
phage development, homeostasis and function.
2. Materials and methods
2.1. Animal experiments
All birds were obtained from the National Avian Research Facility at
The Roslin Institute, University of Edinburgh. Production of the trans-
genic chicken lines used in this study have been previously described
(Balic et al., 2104). All birds were hatched and housed in premises li-
censed under a UK Home Office Establishment License in full com-
pliance with the Animals (Scientific Procedures) Act 1986 and the Code
of Practice for Housing and Care of Animals Bred, Supplied or Used for
Scientific Purposes. All procedures were conducted under Home Office
project licences PPL 70/8940 (for transgenic animals; Prof. Helen Sang)
and PPL 60/4420 (for administration of substances; Prof. Mark
Stevens), according to the requirements of the Animal (Scientific
Procedures) Act 1986, with the approval of local ethical review com-
mittees. Animals were humanely culled in accordance with Schedule 1
of the Animals (Scientific Procedures) Act 1986.
Table 1
List of primary and secondary antibodies used for flow cytometry and immunohistochemistry.
Antibody name/Clone Antigen Isotype Supplier Working concentration μg/ml
Mouse anti-CD45-RPE/clone LT-40 CD45 IgM Southern Biotech 0.8
Mouse anti-chicken Monocytes/Macrophages-RPE/clone KUL01 MRC1L-B IgG1 Southern Biotech 0.4
Mouse anti-Bu-1-RPE/clone AV20 Bu-1a/b IgG1 Southern Biotech 0.1
Mouse anti-chicken MHC II-RPE/clone 2G11 MHC class II β-chain IgG1 Southern Biotech 0.1
Mouse anti-CD3-RPE/clone CT-3 CD3 IgG1 Southern Biotech 0.1
Mouse anti-CD41/61/clone 11C3 Integrin CD41/61 IgG1 Bio-Rad 0.8
Mouse anti-TIM4/clone JH9 TIM4 IgG1 In house (Hu et al., 2016, 2019) 0.1
Mouse IgG1 isotype control/GR13.1 IgG1 In house (Hu et al., 2016, 2019) 0.1
Mouse IgM isotype control-RPE IgM AlphaDiagnostic 0.8
Mouse IgG1 isotype control-RPE IgG1 AlphaDiagnostic 0.1
Fig. 1. (A) Screening of hybridoma supernatant by
indirect ELISA. Clone 6, 22, 23 and 25 recognised
chCSF1 but not the IgY fusion partner. Clone 6 (ROS-
AV181) and 22 (ROS-AV183) were successfully
cloned. (B) ROS-AV181 and 183 recognised non-
tagged chCSF1 and chCSF1-Fc but not the IgY-Fc
fusion partner in an indirect ELISA.
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2.2. Monoclonal antibody production, purification, isotyping, and labelling
Chimeric CSF1-Fc fusion protein was produced as previously de-
scribed (Garceau et al., 2015). The fusion protein has the minimal ac-
tive fragment of chicken CSF1 and the chicken IgY constant heavy chain
domains 3 and 4. ChCSF1-Fc was used as immunogen to immunise
mice. Immunisation and fusion to generate hybridomas was carried out
by Dundee Cell Products (DCP, Dundee, UK). Following fusion, hy-
bridoma supernatants were screened by indirect ELISA for reactivity
with recombinant chCSF1-Fc or diluted chicken serum (as IgY-Fc con-
trol). Indirect ELISA was performed as described previously (Rothwell
et al., 2001). Briefly, assay plates (Nunc Immuno MaxiSorp, Thermo
Fisher Scientific, UK) were coated with recombinant chCSF1 or diluted
chicken serum in Carbonate/Bicarbonate buffer at 4 °C overnight. Hy-
bridoma cultures or purified mAb were added after the pre-coated
plates were washed and blocked with 0.5% (w/v) casein in phosphate-
buffered saline (PBS). After three washes with PBS, plates were then
incubated with goat anti-mouse Ig-horseradish peroxidase (HRP; 1/
1000, Southern Biotech, Cambridge, UK) at room temperature (RT) for
1 h. Peroxidase activity was developed by adding trimethylbenzedine
(TMB) substrate (Thermo Fisher Scientific). The reaction was stopped
by 2N sulfuric acid stop solution. Plates were read at 450 nm in a
SpectraMax 250 microplate spectrophotometer system (Molecular De-
vices, Sunnyvale, CA, USA). Positive wells were single-cell cloned. Two
monoclonal antibodies, designated as ROS-AV181 and ROS-AV183
were purified using HiTrap Protein G affinity columns and dialysed
against PBS using 30 kDa molecular weight cut-off (MWCO) Slide-A-
Lyser cassettes (Pierce, Thermo Fisher Scientific). The concentrations of
mAbs were determined by absorbance at 280 nm with a Nanodrop. The
antibody was isotyped using the IsoStrip Mouse Monoclonal Antibody
Isotyping Kit (Roche) according to the manufacturer's instructions.
Purified antibodies were biotinylated using Sulfo–NHS–LC-LC-biotin
(Thermo Fisher Scientific) and desalted to remove non-reacted biotin
using Zeba™ Spin Desalting Columns (Thermo Fisher Scientific) as per
instructions.
For in vivo studies, large volumes of the neutralising mAb (ROS-
AV183) and IgG1 isotype control antibody (mouse anti-ovine CD335
(GR13.1)) were purified from hybridoma culture and dialysed as above.
Antibody was filtered through a low protein binding syringe 0.2 μm
filters (GE Healthcare Whatman™ Puradisc 25 mm syringe filter) for
sterilisation.
2.3. Development of a capture ELISA assay and comparison of circulating
CSF1 in broilers and layers at different ages
To develop a capture ELISA assay, a chequerboard titration method
was used to determine the optimal concentration of coating antibody
and detecting antibody. After optimisation, a capture ELISA assay was
developed using ROS-AV181 as capture antibody and biotinylated ROS-
AV183 as detecting antibody. Briefly, assay plates were coated with
capture antibody ROS-AV181 at 2 μg/ml overnight at 4 °C. Plates were
washed and blocked as in the indirect ELISA. Plates were incubated
with test samples at RT for 1 h. Serially diluted recombinant chicken
CSF1 (produced in bacteria, Garceau, 2014) was used to generate a
standard curve. Plates were washed and incubated with biotinylated
detecting antibody ROS-AV183 at 0.25 μg/ml at RT for 1 h. After three
washes, plates were incubated with streptavidin–HRP (1:5,000, Pierce)
for a further hour at RT before adding substrate (1-step TMB; Thermo
Fisher Scientific) and then 2N sulfuric acid stop solution. Absorbance
was read at 450 nm.
For comparative analysis of CSF1 levels using the CSF1 ELISA assay,
broiler eggs (Ross 308) and layer eggs (Novogen Brown) were bred in
the National Avian Research Facility at The Roslin Institute. Embryos
were sacrificed for blood on day 19, 20 and chicks on day 1, day 2, day
3, day 7 and day 14. Sera were collected from clotted blood samples
after spinning at 2,000 g for 10 min.
ELISA results were calculated using Graphpad Prism 6.07. Standard
curve was interpolated with Second order polynomial (quadratic).
2.4. Western blotting of tissue lysates and sera
Tissues and sera were collected from 8-week-old Novogen brown
birds. Approximately 10 mg of tissue was homogenized in 500 μL of
cold radioimmunoprecipitation assay buffer (RIPA Buffer) containing
protease and phosphatase inhibitors (Roche) using CK mix homo-
genising tubes and Precellys 24 (Bertin Instrument). After homo-
genisation, samples were centrifuged at 10,000 g for 20 min at 4 °C to
Fig. 2. Western Blot on serum samples and tissue lysates using anti–CSF–1
(ROS-AV181 or ROS-AV183). (A) Western blot showing the two isoforms of
circulating CSF1 in chicken serum. Lane 1 and 3, 18 μl of serum; lane 2 and 4,
9 μl of serum. (B) Western blot showing isoforms of CSF1 in tissue lysates. 1.
Thymus, 2. Bursa, 3. Spleen, 4. Bone Marrow, 5.Cecal Tonsil, 6. Brain 7. Muscle,
8. Heart, 9. Lung, 10. Kidney, 11. Liver, 12. Jejunum.
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pellet cell debris. Protein concentration of total lysates was determined
using Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Fisher
Scientific) according to the manufacturer's instructions.
Tissue lysate and serum samples were treated with SDS-PAGE re-
ducing buffer, denatured for 5 min at 100 °C and loaded onto 4–20%
pre-cast Mini-PROTEAN TGX Gels (Bio-Rad) and transferred onto
0.45 μm pore size Hydrophobic Immobilon-P Transfer Membrane
(Millipore) using a tank transfer method according to the tank's man-
ufacturer instructions (Bio-Rad). Blots were then washed in PBS and
blocked in 0.5% skimmed milk/PBS for 1 h at RT. After washing three
times, blots were incubated in primary antibodies (ROS-AV181, ROS-
AV183 or mouse IgG1 control at 1.0 μg/ml) for 1 h at RT. Blots were
Fig. 3. Localization of CSF1 in the immune tissues.
Tissue sections were processed as in Materials and
Methods. (A and B) CSF1 staining of spleen from a 16
week old chicken. CSF1 staining is localised to the
ellipsoid surrounding the penicillar capillary. CSF1
(Red), and DAPI (blue), scale bar = 20 μm. (C–F)
CSF1 staining on bursa of Fabricius from a 3 day old
chick. CSF1 staining is localised to the cells at the
cortico-medullary junction. CSF1 (Red), IgY (green)
and DAPI (blue). (C and E) Objective lens 20 × ;
scale bar = 20 μm. (D and F) Objective lens 40 × ;
scale bar = 20 μm. (For interpretation of the refer-
ences to colour in this figure legend, the reader is
referred to the Web version of this article.)
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then incubated with goat anti-mouse IgG1-horseradish peroxidase (1/
1000, Southern Biotech) diluted in 0.5% skimmed milk powder/PBS.
Detection was carried out using enhanced chemiluminescence (ECL)
(GE Healthcare Life Sciences), according to the manufacturer's in-
structions.
2.5. Immunofluorescence staining and confocal imaging
Spleen and bursa were isolated from commercial layer chickens
(Hy-Line, UK), washed with PBS and cryo-embedded in Tissue-Tek
Optimal Cutting Temperature (OCT) compound (Sakura Finetechnical).
These tissues were sectioned at 10 μm on a Leica CM1900 cryostat,
placed onto Superfrost Plus (Menzel-Gläser) glass slides and left to dry.
Sections were fixed in ice cold methanol for 20 min and blocked for 1 h
in blocking solution (10% normal horse serum, 0.1%Triton X-100 in
PBS (MST-PBS)) then incubated with anti-CSF1 antibody (ROS-AV181)
for 1 h at RT. After washing with PBS, slides were incubated with goat
anti-mouse IgG1 Alexa Fluor 647 (Invitrogen, 1/500) prior to nuclear
staining with 4′,6-diamidino-2-phenylindole (DAPI. Invitrogen). Slides
were washed in PBS for 30 min on a shaker and mounted using Prolong
Gold anti-fade mounting solution (Invitrogen). Confocal images were
taken on Zeiss LSM 710 inverted microscope and processed using Zen
2012 (Blue Edition, Carl Zeiss Microscopy) or ImageJ software.
Liver samples from CSF1R-eGFP transgenic reporter birds after
subcutaneous injections (described below) were collected in ice cold
PBS and fixed in 4% paraformaldehyde (PFA) overnight, followed by
washing in PBS and storage in 30% sucrose until the tissues sank.
Tissues were then cryo-embedded in OCT and sectioned for staining
with anti-TIM4 (clone JH9, Hu et al., 2016) overnight at 4 °C. Sections
were then incubated with secondary antibodies; Donkey anti-mouse IgG
(H + L) (Invitrogen) to detect TIM4 and Rabbit anti-GFP Alexa Fluor
488 (Invitrogen) to detect CSF1R-eGFP. Slides were then washed,
Fig. 4. Flow cytometric analysis of surface expression of CSF1R on BMDM. BMDMs were cultured with CSF1 for 6 days. At this point, half of the cells were starved of
CSF1 overnight (no CSF1) and the other half were cultured with CSF1 (with CSF1). Following a further 24 h of culture, BMDM were stimulated with LPS for 3 h. Cells
were stained with either anti-CSF1-AF647 or CSF1-Fc-AF647. All histograms are representatives of three independent experiments. (A) Comparison of the staining
profiles of CSF1 and CSF1-Fc between cells starved of CSF1 (dotted line) or cultured with CSF1 (solid line). (B) Comparison of the staining profiles between cells non-
stimulated (solid line) or stimulated with LPS (dotted line) for 3 h. Cells were cultured with CSF1 or starved of CSF1 as in A.▲ Isotype controls.
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mounted and visualised as described above. Images were processed
using ImageJ. TIM4+ cells were counted in five different images from
five different areas of liver sections per animal per treatment.
2.6. Flow cytometric analysis
CSF1-Fc was prepared as described previously (Garceau et al.,
2015). Anti-CSF1 and CSF1-Fc were conjugated to Alexa Fluor 647
(AF647) using the AF647 Microscale Protein labelling kit (Thermo
Fisher Scientific) according to manufacturer's instructions.
To measure surface CSF1 on BMDM, chicken BMDMs were cultured
from bone marrow cells from hatchlings in the presence of recombinant
chicken CSF-1 as previously described (Garceau et al., 2010). On day 6
of culture, cells were refreshed with culture medium with CSF1 or
starved of CSF1 for 18 h. On day 7, cells were stimulated with 0.5 μg/ml
of lipopolysaccharide (LPS; E. coli serotype 055:B5, Sigma) for 3 h or
non-stimulated. Cells were washed with cold FACS buffer (PBS/1.0%
BSA/0.05% Sodium azide), incubated in anti-CSF1- Alexa Fluor 647 or
CSF1-Fc- Alexa Fluor 647 at 4 °C for 30 min.
For flow cytometric analysis of primary cells, single cell suspensions
were isolated from blood and spleen. EDTA-treated blood was diluted to
2 ml and gently overlaid onto the same volume of Lymphoprep with a
density 1.077 g/ml (STEMcell Technologies) prior to centrifugation at
400g without brake for 30 min. Cells at the interface were carefully
collected and washed twice with FACS buffer. Spleens were collected in
cold PBS, dispersed through a 100 μm cell strainer and isolated by
centrifugation over Lymphoprep as described above for blood cells.
Cells were then blocked with FACS buffer for 5 min and incubated on
ice with monoclonal antibodies listed in Table 1 at appropriate con-
centrations as determined by titration assays. Cells were washed twice
and re-suspended in FACS buffer and analysed using a BD LRSFortessa
(BD Biosciences, UK). SYTOX® Blue Dead Cell Stain (1.0 μM, In-
vitrogen) was added 5 min prior to analysis to exclude dead cells.
Doublets were discriminated based on signal processing (SSC-A/H or
FSC-A/H). Data were analysed using FlowJo software (FlowJo, Ashlan,
OR. USA).
2.7. Neutralisation of CSF1 activity
To determine the ability of antibodies to neutralise CSF1 in vitro,
recombinant CSF1 was pre-incubated with anti-CSF1 mAbs or a mouse
IgG1 control at 37 °C for 2 h before addition to bone marrow or Ba/F3
cells expressing the chicken CSF1R (Garceau et al., 2010). Chicken bone
marrow cells from embryonic day (ED) 20 Novogen embryos were
Fig. 5. Development of a capture ELISA assay and comparison of CSF1 levels in sera between broiler and layer birds. (A) Standard curve of capture ELISA assay. (B
and C) CSF1 concentrations in sera from broilers (panel B) and layers (panel C) from embryonic day (ED) 19 to day 14 after hatch (n = 10). (D) Comparison of CSF1
concentrations in sera from broilers (Blue) and layers (Red). A non-parametric Mann–Whitney test was used to analyse differences of CSF1 levels between time
intervals (panels B and C) and bird types (panel D). P values < 0.05 were considered significant. (For interpretation of the references to colour in this figure legend,
the reader is referred to the Web version of this article.)
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cultured with CSF1 and re-fed every 2–3 days with the same fresh
media and incubated for 7 days. Ba/F3 cells expressing chicken CSF1R
(Garceau et al., 2010) were maintained in culture with complete RPMI
medium supplemented with 10% heat-inactivated foetal bovine serum
(FBS), 2 mM L-glutamine and antibiotics (100 g/ml penicillin, 100 g/ml
streptomycin) and 5% conditioned medium from X63 Ag8-653 mye-
loma cells carrying an expression vector for IL-3 (Karasuyama and
Melchers, 1988) at 37 °C, 5% CO2 prior to assays for cellular metabolic
activity using the tetrazolium dye MTT. Cells were washed twice with
PBS to remove any IL-3, and plated in a 96 well plate in triplicate at
4 × 104 cells/well in 100 μl of complete RPMI without X63 super-
natant. Cells were treated with serial dilutions of chicken CSF1 and
incubated for 72 h at 37 °C, 5% CO2. 10 μl of MTT (Sigma-Aldrich)
stock solution (5 mg/ml) was added directly to each well to achieve a
final concentration of 0.5 mg/ml and incubated at 37 °C for 3 h before
adding 100 μl of solubilisation solution (0.1 M HCl, 10% Triton X-100
Fig. 6. Neutralising effect of mAbs to CSF1. (A) Chicken CSF1 was titrated out on Ba/F3 cells stably transfected with CSF1R (Ba/F3-CSFR) to determine a suitable
concentration for neutralising assay. 400 ng/ml was chosen. (B) Ba/F3-CSFR were cultured with CSF1, CSF1 pre-incubated with either ROS-AV181 or 183, mouse
IgG1 control or without CSF1 for 72 h before performing MTT assays. Cells cultured with CSF1 or CSF1 pre-incubated with ROS-AV181 or isotype control pro-
liferated. Cells cultured with CSF1 pre-incubated with ROS-AV183 were dead when>2.5 μg/ml of antibody was used. Assays were carried out in triplicate and
representative data from three independent experiments are shown. (C) Chicken bone marrow cells were cultured with CSF1 pre-incubated with mAbs, CSF1 only or
without CSF1. Original magnification objective lens 10X.
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and isopropanol) and incubation overnight. Plates were read at 570 nm.
2.8. Subcutaneous injection of anti-CSF1 in hatchlings
Seventeen newly hatched CSF1R-eGFP transgenic chicks (Balic
et al., 2014) were weighed and divided into two groups with matching
body weight. One group of chicks was injected subcutaneously in the
breast muscle region with neutralising anti–CSF–1 antibody (ROS-
AV183) (10 mg/kg, ca. 500 μg per bird) on each of four consecutive
days. The control group was treated with isotype control antibody
Fig. 7. The effect of anti-CSF1 treatment on lymphoid organs in hatchling birds. CSF1R-eGFP reporter (MacGreen) birds received anti-CSF1 (ROS-AV183) or mouse
IgG1 control antibody subcutaneously for four consecutive days from day of hatch and were sacrificed on day 7. (A–C) Mean fluorescence intensity (MFI) and surface
area between the two groups obtained using Zen blue 2012 software, showing mean values of spleen, cecal tonsil and bursa. Error bars represent standard error of the
mean. Significance was indicated by *P < 0.05 using a Mann–Whitney test. (D–F) Representative whole mount images of lymphoid tissues spleen, cecal tonsil and
bursa obtained using Zeiss Axio Cam HR microscope, scale bar = 1 mm. (For interpretation of the references to colour in this figure legend, the reader is referred to
the Web version of this article.)
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(mouse anti-ovine CD335, clone GR13.1). Body weights of all birds
were measured on day 1, 2, 3, 4 and day 7. Blood was collected for flow
cytometry analysis into a BD Vacutainer collection tube and analysed
by Flow Cytometry as above. Lymphoid tissues including spleen, cecal
tonsils and bursa were collected and placed in PBS in a Petri dish for
whole mount imaging performed using a Zeiss Axio Cam HR fluorescent
microscope. Surface area of the lymphoid tissues and mean fluores-
cence intensities of CSF1R transgene was measured using Zeiss blue
2012 edition. Average values with standard deviation graphs were
plotted using GraphPad Prism 7 software. All results were analysed for
statistical significance with a non-parametric Mann Whitney test.
Spleens were cut into halves for flow cytometric analysis or immuno-
fluorescence staining. All other tissues were fixed in 4% PFA for im-
munofluorescence staining as described above.
2.9. microCT scanning of bones and TRAP staining
Seventeen left femur bones were subjected to micro-CT (computed
tomography) scanning to analyse bone volume and trabecular number.
Femurs were fixed in 4% PFA overnight and stored in 70% ethanol at
4 °C until embedding in 0.5% agarose gel in a universal tube for
scanning. Skyscan 1172 at 60 kV, 150 μA at a resolution of 5 μm was
used. Restructuring 3D image was obtained using CTVox programme.
Tartrate-resistant acid phosphatase (TRAP) staining was performed
as described previously (Sauter et al., 2014). Briefly, right femur bones
were decalcified, embedded, and sectioned by the Royal (Dick) School
of Veterinary Studies Clinical Pathology Laboratory (University of
Edinburgh, UK). Four-micrometer thick sections were stained with an
acid phosphatase leukocyte kit (Sigma) according to the manufacture's
protocol. The staining results were observed by Nikon Ni2 bright field
microscopy and images were taken under 10 × objective lens. The
positively-stained osteoclasts were counted following identification
using their red colour, location in resorption pits, large size, distinctive
shape and presence of multiple nuclei. Two sections from each of 5–6
treated and control birds bird were stained and 3–5 views were imaged
for quantification of osteoclasts. Statistical differences were analysed
with a non-parametric Mann Whitney test.
3. Results
3.1. Production of two monoclonal antibodies to chicken CSF1 and
prediction of CSF1 isoforms
To generate anti-CSF1 monoclonal antibodies, mice were im-
munized with chicken CSF1-Fc. Spleens were extracted and fused with
myeloma cells by standard protocols. Hybridoma supernatants were
screened to identify clones that produced antibodies recognising CSF1-
Fc, but not the IgY fusion partner, in an indirect ELISA (Fig. 1A). Two of
the positive hybridomas, designated as ROS-AV181 and ROS-AV183,
were successfully cloned and tested in a range of applications. Fig. 1B
shows these two mAbs recognise recombinant chCSF1 as well as CSF1-
Fc but do not bind IgY-Fc as tested by indirect ELISA.
In mammals, the CSF1 locus encodes at least three mRNA splice
isoforms through differential splicing. The protein products include 3
biologically active isoforms: a membrane-spanning cell-surface glyco-
protein, and secreted glycoprotein and proteoglycan isoforms. In mice,
the relative importance of these isoforms has been explored through
transgenic (re)expression in Csf1op/op mice that lack endogenous CSF1
(Nandi et al., 2006; Ryan et al., 2001); (Dai et al., 2004). The genomic
structure of CSF1 is similar in chickens, and initial characterization of
Fig. 8. The effect of anti-CSF1 treatment on blood leukocytes and splenocytes. Blood leukocytes and splenocytes were isolated, stained with KUL01, anti-MHC class II
and anti-Bu-1 and analysed by flow cytometry. (A–C) The profiles of peripheral blood cells from CSF1R-eGFP birds treated with anti-CSF1 (n = 8) or with mouse
IgG1 isotype control antibody (n = 6). Significance is indicated by *P < 0.05 using a Mann–Whitney test. (D–F) The profiles of spleen cell suspension from CSF1R-
eGFP birds treated with anti-CSF1 (n = 9) or an isotype control antibody (n = 8). Significance is indicated by ***P < 0.001 using a Mann–Whitney test.
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Csf1 mRNA indicated that all three isoforms were likely to exist in birds
(Garceau et al., 2010). Western blot analysis of serum (Fig. 2A) with the
two different anti-CSF1 antibodies confirmed the presence of two major
bands, consistent with the secreted proteoglycan (monomeric Mr of ca
120 kDa) and glycoprotein (monomeric Mr of ca. 35–40 kDa) isoforms.
A faint low Mr band around 13–15 kDa could be the core, un-
glycosylated and monomeric active CSF1 molecule, or may be a de-
gradation product. In extracts of tissues (Fig. 2B), the high Mr, pre-
sumptive proteoglycan isoform was dominant and was most abundant
in the three immune tissues tested, namely thymus, bursa and spleen.
The low Mr band detected in the circulation was notably highly ex-
pressed in bone marrow.
3.2. Localization of CSF1 in the immune tissues and its expression on
BMDM
To determine the location of CSF1 in the immune tissues, we carried
out immunofluorescence staining of the spleen and bursa. In the spleen
(Fig. 3A and B), CSF1 staining was concentrated to the splenic ellipsoid,
the major location of active phagocytosis of blood-borne particles in the
avian spleen, with some functional similarities to the marginal zone of
rodent spleen (Jeurissen, 1993; Zhang et al., 2015). In the bursa
(Fig. 3C–F), CSF1 expression was localised to the cortico-medullary
boundary, which we have previously shown to contain a prominent
population of TIM4+ macrophages (Hu et al., 2019).
In separate in vitro studies, we generated RNAseq profiles from
chicken macrophages grown in CSF1 (Freem et al., 2019). The data
indicated that, unlike mouse bone marrow-derived macrophages, but in
common with all other mammalian species studied including rats and
humans, chicken macrophages grown in CSF1 express high levels of
their own growth factor. We used the RNAseq data to investigate the
nature of the CSF1R transcript(s) in chicken BMDM, confirming that
they make the longer form of the mRNA encoding an integral mem-
brane form of the protein (Freem et al., 2019). Based upon the mRNA
Fig. 9. The effect of anti-CSF1 treatment on TIM4+ Kupffer cells. (A) Confocal images of Kupffer cells as detected by anti-chicken TIM4 mAb (red) staining in liver
tissue (n = 8/9) using LSM 710 inverted microscope. Representative image from three birds from each treatment. Green indicates CSF1R transgene expression, red
indicates TIM4+ cells and blue denotes nuclei. Scale bar = 20 μm. (B) The numbers of TIM4+ Kupffer cells per image were quantified using ImageJ from 5 different
images from 5 different regions of liver sample per bird per treatment at 40 × magnification. The graph indicates the average count of TIM4+ cells (red channel) per
image with standard deviation between the mouse IgG1 and anti-CSF1 treated group. **** indicates significance at P < 0.0001 using a Mann–Whitney test. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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expression, we examined whether the anti-CSF1 antibody would bind to
the surface of chicken BMDM. To remove exogenous CSF1, cells were
washed and starved overnight of CSF1. In contrast to mouse BMDM,
which require exogenous CSF1 for survival (Griggs and Zinkewich-
Peotti, 2009; Sester et al., 1999), chicken BMDM remain viable after
CSF1 removal. To detect the cell surface expression of CSF1R, re-
combinant CSF1-Fc labelled with Alexa Fluor® 647 (CSF1-Fc-AF647)
was used. The use of the ligand to analyse surface CSF1R has been
applied previously in mice and rats (Hawley et al., 2018; Pridans et al.,
2018; Rojo et al., 2019). Fig. 4 shows that the entire BMDM population
stained for surface CSF1 (as detected by anti-CSF1 antibody) or CSF1R
(as detected by CSF1-Fc-AF647). Panel A shows that the binding of the
labelled ligand was only marginally increased when the cells were
starved of exogenous CSF1 overnight, in contrast to the massive upre-
gulation seen in CSF1-starved mouse BMDM (Sester et al., 1999). On
the other hand, cell surface CSF1 immunoreactivity was greatly reduced
in the cells incubated without CSF1 overnight. In mouse macrophages,
stimulation with bacterial lipopolysaccharide (LPS), or other toll-like
receptor agonists, causes rapid release of CSF1R from the cell surface
(Sester et al., 1999). Like mouse, chicken BMDM respond to LPS with a
cascade of inflammatory gene activation (Garcia-Morales et al., 2015),
but there was no impact after 3 h treatment on the level of surface
CSF1-Fc-AF647 binding (Fig. 4B). Instead, LPS caused a significant re-
duction in cell surface CSF1 in the CSF1-starved cells, but not in those
that have been maintained in CSF1 (Fig. 4B).
3.3. Comparative analysis of circulating CSF1 levels in layers and broilers
as detected by capture ELISA
We next tested combinations of the available monoclonal antibodies
to generate a sandwich capture ELISA, using recombinant bacterial-
expressed chicken CSF1 as a standard. The optimized assay had a de-
tection limit around 62.5 pg/ml to 2 ng/ml (Fig. 5A). In mice, circu-
lating CSF1 was reported to be highest in fetal and neonatal serum,
around 30–40 ng/ml, and declined in the postnatal period (Roth and
Stanley, 1996). In mice, both CSF1 and CSF1R mutations produce se-
vere post-natal growth retardation (Chitu and Stanley, 2006). Broiler
chickens have been selected for rapid post-hatch weight gain. We
therefore used the CSF1 ELISA to examine expression during embryonic
development and the phase of rapid post-hatch growth and to compare
the time courses of circulating CSF1 in layer and broiler birds (Fig. 5 B-
D). The circulating CSF1 concentration prior to hatch was 10-fold lower
than reported in mice, around 3–5 ng/ml in late incubation. The level
increased transiently in both layers and broilers around the day of
hatch. On average the level of CSF1 in broilers was higher than in
layers, but more variable. The differences between broiler and layer
birds were significantly greater from ED20 to post hatch D3.
3.4. Confirmation of neutralising activity of the anti-CSF1 (ROS-AV183)
antibody in vitro
To assess whether antibodies would block CSF1 action, we used Ba/
F3 growth factor-dependent cells expressing the chicken CSF1R
(Garceau et al., 2010). Fig. 6A shows the dose-response curve for
chicken CSF1 using this assay. Note that the minimal active con-
centrations (around 5 ng/ml) are in the range of serum concentrations
measured above. Fig. 6B shows that one of the anti-CSF1 antibodies we
generated, ROS-AV183, was able to completely block the action of a
just-maximal concentration of chicken CSF1. We confirmed the
biological activity by demonstrating that ROS-AV183, but not ROS-
AV181, blocked the ability of CSF1 to generate macrophages from bone
marrow progenitors (Fig. 6C). The relatively stoichiometry (2.5 μg/ml
blocking 400 ng/ml of CSF1) suggested that the antibody could have
sufficient affinity to block actions of CSF1 in vivo.
3.5. Anti–CSF–1 antibody treatment in hatchlings
To test the impact of inhibition of CSF1 in vivo, we utilised a CSF1R
reporter line described previously (Balic et al., 2014) and treated
newly-hatched birds with the neutralising antibody ROS-AV183 for four
consecutive days. Treated birds showed no signs of illness and devel-
oped normally. By contrast to the impact of anti-CSF1 treatment in mice
(Wei et al., 2005), there was no effect on post-hatch body weight gain
(data not shown). To examine the transgene expression in major lym-
phoid tissues including cecal tonsil, bursa and spleen, the mean fluor-
escence intensity (MFI) and surface area was obtained from whole
mount images analysis using Zeiss blue software. The surface area of
different organs was correlated to body weight of each bird, regardless
of treatment. There was no significant difference in the MFI or the
surface area of spleen (Fig. 7A) but a significant decrease in the MFI of
transgene expression was detected in both cecal tonsil (Fig. 7B) and
bursa (Fig. 7C) after anti-CSF1 treatment. Surface area of bursa and
cecal tonsil tissue remained unaffected. Representative images com-
paring treated and untreated spleen, cecal tonsil and bursa are shown in
Fig. 7D–F. The decrease in CSF1R-transgene positive cells in cecal tonsil
and the bursa of Fabricius from birds treated with anti-CSF1 was further
detected by confocal microscopy using anti-eGFP antibody
(Supplemental Material Fig. S1).
Fig. 8 shows the profiles of peripheral blood mononuclear cells from
CSF1R-eGFP birds treated with anti-CSF1 or an isotype control anti-
body. The blood cells were stained for the monocyte marker KUL01, B
cell marker BU.1 and class II MHC. The proportions of the different cell
populations were variable between birds, regardless of treatment. There
was no significant effect of anti-CSF1 on CSF1R+ KUL01+ monocytes
(Fig. 8A). Both MHC class II (Fig. 8B, which labels both B cells and
monocytes) and Bu-1 (Fig. 8C) staining indicated a marginal reduction
in circulating B cells. In the spleen, anti-CSF1 treatment had no impact
on the CSF1R+, KUL01+ populations (Fig. 8D). However, the numbers
of MHC II+ cells and Bu-1+ cells in the spleen were significantly re-
duced (Fig. 8E and F).
The liver tissue resident macrophage population (Kupffer cells) in
mice is rapidly depleted by treatment with anti-CSF1R antibody
(MacDonald et al., 2010) or anti-CSF1 (Lin et al., 2019). In the chick,
the CSF1R-reporter is not expressed by Kupffer cells (KC), although they
express high levels of CSF1R mRNA (Hu et al., 2019). To assess the
effect of anti-CSF1 in the liver, we used an antibody against the KC
marker TIM4 (Hu et al., 2019). Fig. 9 shows that TIM4+ cell population
was almost completely ablated by anti-CSF1 treatment. Representative
immunohistochemistry images from three individual animals are shown
in Fig. 9A. Fig. 9B shows that the average TIM4+ cell number per image
was significantly reduced in the anti-CSF1 treated group compared to
the mouse IgG1 control group.
As CSF1 mRNA and protein were highly-expressed in bone marrow
(Fig. 2B), and treatment of hatchling birds with CSF1-Fc increased bone
density, trabecular thickness and trabecular number within one week
(Garceau et al., 2015), we examined the impact of anti-CSF1 treatment
on the same parameters. The bone volume and trabecular number were
significantly reduced in the treated birds, and correspondingly, the
Fig. 10. The effect of anti-CSF1 treatment on bone. (A) Comparison of bone volume and trabecular thickness, number and separation by microCT scanning of femur
bones between chicks treated with mouse IgG1 or anti-CSF1 (N = 7/8). Significance is indicated by *P < 0.05, using a Mann–Whitney test. (B) Representative 3D
images from birds treated with mouse IgG1 and anti-CSF1 antibody obtained using CTVox programme. Scale bar = 1.0 mm. (C) Comparison of TRAP+ osteoclasts
(black arrows) in the bone between mouse IgG1 and anti-CSF1 treated groups. Significance is indicated by ***P < 0.005, using a Mann–Whitney test. (D)
Representative TRAP staining images of mouse IgG1 and anti-CSF1 treated birds. Scale bar = 50 μm.
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trabecular separation was increased (Fig. 10A and B). TRAP staining
results showed that bone osteoclasts (OCL) were significantly reduced
by anti-CSF1 treatment (Fig. 10C and D).
4. Discussion
We have generated anti-chicken CSF1 antibodies and utilised them
to study the biology of CSF1 in the chicken. In mammalian systems,
there is surprisingly little information on the location of CSF1 in tissues,
and to our knowledge, no published staining with an anti-CSF1
monoclonal in any mammalian species. Somewhat at odds with the
protein expression we have observed by Western blotting, CSF1 mRNA
is widely expressed in cells and tissues in a recently generated chicken
expression atlas (www.biogps.org/chickenatlas) (Bush et al., 2018).
Nevertheless, chicken BMDM had the highest level of CSF1 mRNA ex-
pression of any cell or tissue assay including fibroblasts (Garceau et al.,
2010). The difference between the mRNA and protein data likely re-
flects differences in production of secreted versus cell membrane forms
of the protein in different tissues and cell types. A Csf1-lacZ reporter
gene was used previously in mice to locate CSF1-expressing cells (Ryan
et al., 2001). They reported the presence of Csf1-lacZ positive cells in
the marginal zone of spleen and to a lesser extent in red pulp, and in
outer cortical areas of lymph nodes, where macrophages are con-
centrated. A recent study located CSF1 in mouse lymph nodes to lym-
phatic endothelial cells and confirmed the function in maintenance of
the subcapsular sinus macrophage population (Mondor et al., 2019). In
most other tissues, the LacZ reporter was associated with epithelial and
glandular structures. These authors concluded that CSF1 was mainly
expressed by cells of mesenchymal origin. Indeed, the source of CSF1 in
mice in vivo is commonly attributed to mesenchymal (endothelial cells,
fibroblasts, osteoblasts, adipocytes) and epithelial cells (Stanley and
Chitu, 2014). In mice, Csf1 mRNA is not expressed by BMDM grown in
CSF1, nor by any isolated tissue macrophage population assayed by the
ImmGen consortium (www.immgen.org). However, CSF1 mRNA was
shown to be inducible during differentiation in human monocytes by
growth factors and phorbol esters (Horiguchi et al., 1986, 1987, 1988).
The highest level of expression of CSF1 mRNA in the FANTOM5 human
transcriptional atlas is in monocyte-derived macrophages (Consortium
et al., 2014). Csf1 mRNA is also expressed at high levels in pig (Freeman
et al., 2012) and rat (Rojo et al., 2019) BMDM. Using the anti-CSF1
antibody, we confirmed here that chicken BMDM also express CSF1 on
their surface, and the level appears to be regulated further by exo-
genous CSF1. Unlike mouse BMDM, once progenitors have differ-
entiated in response to CSF1 the resulting chicken BMDM do not de-
pend on exogenous CSF1 for survival, consistent with a role for
autocrine CSF1.
Three species of CSF1 were detected in serum by Western blotting
(Fig. 2A). We used the anti-CSF1 antibodies to develop an ELISA and to
measure the concentration of circulating CSF1. The level we detected,
in the low ng/ml range, is consistent with the apparent saturation of the
CSF1R receptor with ligand in bioassays (Fig. 6B). We previously de-
monstrated that the availability of CSF1 in hatchling birds is not sa-
turating for monocyte-macrophage generation. The administration of
exogenous CSF1-Fc produced a massive expansion of circulating and
tissue cell populations expressing CSF1R reporter genes (Garceau et al.,
2015). Here we characterized a neutralising antibody and showed that
it was able to block CSF1 biological activity in vitro (Fig. 6). We were
therefore able to demonstrate that CSF1 was essential for the devel-
opment and/or maintenance of tissue macrophages.
We also analysed the impact of anti-CSF1 on the development of the
bone. Anti-CSF1 treatment produced a reduction in overall bone density
and trabecular volume (Fig. 10), the reciprocal of the impact of CSF1-Fc
treatment (Garceau et al., 2015). In mice, CSF1R is expressed by bone-
resorbing osteoclasts (OCL). CSF1-deficient mice are osteopetrotic, and
OCL are ablated in adult mice treated with anti-CSF1R leading to an
increase in bone density and trabecular volume. Paradoxically,
treatment of mice with CSF1-Fc also increased bone density despite an
increase in OCL number (Gow et al., 2014). This apparent conflict
probably arises because ossification mediated by osteoblasts depends
upon a novel macrophage populations that is also CSF1-dependent
(Batoon et al., 2019). Our studies in chicken are conducted in juvenile
birds with rapid bone growth. We speculate that the elevated CSF1 at
hatch (Fig. 3), and the higher levels apparent in the rapidly growing
broiler birds, may have a regulatory function in skeletal growth.
In mice, although exogenous CSF1 can massively expand blood
monocyte numbers (Yao et al., 2014), CSF1 is not required for mono-
cyte production. Anti-CSF1R antibody administration to adult mice did
not alter the number of monocytes, although it did selectively block
their differentiation to a non-classical phenotype (Gow et al., 2014).
There was no effect of anti-CSF1 on monocyte numbers in the treated
chick (Fig. 8). At present, we do not have any evidence for functional
heterogeneity of chicken monocytes, and anti-CSF1 did not alter ex-
pression of the markers we currently have available (MHC Class II,
KUL01).
Consistent with the impact of anti-CSF1R in mice, anti-CSF1 treat-
ment did impact on some tissue macrophage populations. There was
almost complete loss of the TIM4+ KC population in the liver (Fig. 9),
and partial loss of the CSF1R-transgene positive cells in the bursa and
cecal tonsil (Fig. 7). Given the very high level of CSF1 protein in lym-
phoid organs, the antibody may be less able to compete with en-
dogenous ligand in these tissues. In the peripheral blood and in spleen
and bursa, there was an apparent selective effect on B cell numbers. A
selective defect in B cell lymphopoiesis was also reported in analysis of
a Csf1 knockout mouse (Harris et al., 2012). Transgenic expression of
the proteoglycan form of CSF1 was able to restore B cell numbers in
BM, blood and spleen (Nandi et al., 2006). Clearly the biology is dif-
ferent in birds, in which B cells are produced by the bursa and no
classical lymph node structures have been identified to date. There is no
evidence that CSF1R is expressed in chicken B cells (Balic et al., 2014;
Hu et al., 2019). Accordingly, we suggest that CSF1-dependent mac-
rophages in the bursa and spleen provide trophic factors that can in-
fluence the development or survival of B cells. One macrophage-de-
pendent candidate regulator of bursal B cell development is B cell
activating factor (BAFF, TNFSF13B) (Koskela et al., 2004). In the
chicken expression atlas (www.biogps.org/chickenatlas), Tnfsf13b
mRNA is enriched in bursa, expressed by BMDM, and strongly induced
following stimulation with LPS.
5. Conclusion
We have produced two mouse monoclonal antibodies to chicken
CSF1 and developed one capture ELISA assay to quantify native CSF1.
Antibody ROS-AV183 neutralised the bioactivities of chCSF1 in vitro.
Treatment of hatchlings using this neutralising antibody in vivo im-
pacted on some tissue macrophage populations. These antibodies are
new tools to study the roles of CSF1 in birds.
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